Abstracts Archive - Page 2561 of 2607 - ACR Meeting Abstracts

Abstract Number: 644 • 2012 ACR/ARHP Annual Meeting
Pulmonary Hypertension in Systemic Lupus Erythematosus: A 6-Year Follow-up Study Cohort
Claudia Hübbe-Tena¹, Selma Gallegos-Nava¹, Rafael Bojalil² and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) may present hemodynamic alterations including pulmonary hypertension (PH). Echocardiography (ECHO) is a noninvasive imaging technique useful to classify pulmonary hypertension…
Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Melissa E. Munroe¹, Jourdan R. Anderson², Joan T. Merrill³, Joel M. Guthridge⁴, Virginia C. Roberts⁴, Gillian M. Air⁵, Linda F. Thompson⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Biochemistry, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…
Abstract Number: 646 • 2012 ACR/ARHP Annual Meeting
Comparison of the Lupusqol and SF-36 Scores As Valid Measures of Change in Health Related Quality of Life
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez², Shahrzad Taghavi-Zadeh³ and D. D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The LupusQoL questionnaire is a disease-specific instrument for adults with lupus while the short form-36 (SF-36) is a generic questionnaire. We aimed to compare…
Abstract Number: 647 • 2012 ACR/ARHP Annual Meeting
Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years
Murray B. Urowitz¹, Dominique Ibanez¹, D. D. Gladman², SLICC³ and Systemic Lupus International Collaborating Clinics (SLICC)³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose : There is a high prevalence of premature atherosclerosis among patients with SLE, with a risk 7-9 times that of the general population. The…
Abstract Number: 648 • 2012 ACR/ARHP Annual Meeting
Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus: Incidence Over a Ten Year Period
D. D. Gladman¹, Dominique Ibanez², Murray B. Urowitz² and SLICC³, ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: A large multicentre multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. The purpose of this study was to…
Abstract Number: 649 • 2012 ACR/ARHP Annual Meeting
Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus
Evelyne Vinet¹, Sasha Bernatsky², Mohammed Kaouache², Emil P. Nashi³, Christian A. Pineau³, Ann E. Clarke⁴, Robert W. Platt⁵, Meggan C. Mackay⁶ and Cynthia Aranow⁷, ¹McGill University Health Centre, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Recent experimental evidence suggests that anti-DNA antibodies, cross-reacting with brainstem neuronal receptors, induce apoptosis and cause a marked preferential loss of female foetuses in…
Abstract Number: 650 • 2012 ACR/ARHP Annual Meeting
Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences Between Patients with Positive/Negative Lupus Anticoagulant
Andrea Hinojosa-Azaola¹, Alba Cicero-Casarrubias¹, Mario César Ocampo-Torres¹, Juanita Romero-Díaz¹ and Jorge Sánchez-Guerrero², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombosis in patients with Systemic Lupus Erythematosus (SLE) is a major cause of morbidity, it occurs in 9-37%, at younger age, and it represents…
Abstract Number: 611 • 2012 ACR/ARHP Annual Meeting
Impaired Diffusion Tensor Imaging Findings in the Corpus Callosum and Cingulum May Underlie Impaired Learning and Memory Abilities in Systemic Lupus Erythematosus
Daphna Paran¹, Elissa Ash², Ira Litinsky¹, Valerie Aloush¹, Marina Anouk¹, Dan Caspi³, Talma Hendler⁴ and Irit Shapira-Lichter⁴, ¹Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ²Neurology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Functional Brain Center, Wohl Institute for Advanced Imaging, Tel-Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel
Background/Purpose: Memory impairment is prevalent in systemic lupus erythematosus (SLE), however the pathogenesis is unknown. In a previous functional Magnetic Resonance Imaging (MRI) study we…
Abstract Number: 612 • 2012 ACR/ARHP Annual Meeting
Thrombosis Recurrence in Systemic Lupus Erythematosus Patients with and without Antiphospholipid Antibodies
Ibrahim AlHomood¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To determine the outcome of thrombotic events in the presence and absence of antiphospholipid antibodies (aPL) in patients with systemic lupus erythematosus (SLE).…
Abstract Number: 613 • 2012 ACR/ARHP Annual Meeting
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
In-Woon Baek¹, Ki-Jo Kim², Ji-Young Kim³, Su-Jung Park³, Chong-Hyeun Yoon⁴, Wan-Uk Kim⁵ and Chul Soo Cho⁶, ¹Internal medicine, Catholic University of Korea, Callege of Medicine, Seoul, South Korea, ²Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, ⁴Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁵Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶St Marys Hospital, Seoul, South Korea
Background/Purpose: Syndecan-1(SDC1), a transmemebrane heparan-sulfate glycoprotein, is predominantly expressed by plasma cells and is a receptor for a proliferation-inducing ligand (APRIL). SDC-1 is readily shed…
Abstract Number: 614 • 2012 ACR/ARHP Annual Meeting
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Roger A. Levy³, Sandra V. Navarra⁴, Jill P. Buyon⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Ricard Cervera⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Internal Medicine, Univ Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Predicting which SLE patients are at increased risk for clinically meaningful flares may be useful in making management decisions. The purpose of this analysis was to…
Abstract Number: 615 • 2012 ACR/ARHP Annual Meeting
Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Michelle Petri¹, Ronald F. van Vollenhoven², Roger A. Levy³, Sandra V. Navarra⁴, Ricard Cervera⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Jill P. Buyon⁷, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Karolinska University Hospital, Stockholm, Sweden, ³Medicine, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Hospital Clinic, Barcelona, Spain, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Identification and validation of potential serologic biomarkers of clinically meaningful SLE flare are major unmet medical needs in clinical practice and trials. The purpose…
Abstract Number: 616 • 2012 ACR/ARHP Annual Meeting
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Wendy Cai¹, Cecil Chen¹, Z. John Zhong¹, William W. Freimuth¹, William Lewis² and David Subich³, ¹Human Genome Sciences, Inc., Rockville, MD, ²Covance Clinical Research Unit, Inc., Dallas, TX, ³Covance Clinical Research Unit, Inc., Daytona Beach, FL
Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the…
Abstract Number: 617 • 2012 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels Reflect Organ Damage in Systemic Lupus Erythematosus
Helena Enocsson¹, Jonas Wetterö², Thomas Skogh³ and Christopher Sjöwall⁴, ¹Deparment of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden
Background/Purpose: Disease activity assessment in systemic lupus erythematosus (SLE) remains a challenge due to lack of reliable biomarkers and disease heterogeneity. Ongoing tissue inflammation can…
Abstract Number: 618 • 2012 ACR/ARHP Annual Meeting
BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year
Eric Zollars¹, Hong Fang², Jadwiga Bienkowska³, Norm Allaire³, Susan Kalled³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Biogen Idec Inc., Cambridge, MA
Background/Purpose: The search for a marker of SLE disease activity has included inflammatory markers, chemokines and gene signatures. We explored the ability of the BAFF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].